Ikena Oncology, Inc. ( IKNA ) NASDAQ Global Market

Cena: 1.4 ( 4.1% )

Aktualizacja 07-10 21:58
NASDAQ Global Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 14
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 52%
Ilość akcji: 48 258 100
Debiut giełdowy: 2021-03-26
WWW: https://ikenaoncology.com
CEO: Dr. Mark Manfredi Ph.D.
Adres: 645 Summer Street
Siedziba: 02210 Boston
ISIN: US45175G1085
Opis firmy:

Ikena Oncology, Inc., ukierunkowana firma onkologiczna, koncentruje się na opracowywaniu leków dostosowanych do grup pacjentów zdefiniowanych przez biomarker dla określonych niezaspokojonych potrzeb. Jego głównym kandydatem do produktu onkologii jest IK-930, doustny inhibitor małej cząsteczki w zakresie powiązanej domeny z transkrypcją, czynnik transkrypcyjny w szlaku sygnałowym Hippo. Opracowuje również program inhibitorów małych cząsteczek przeciwko ERK5 w szlaku sygnałowym RAS; IK-175, doustny inhibitor receptora węglowodorowego arylowego; i IK-007, doustny selektywny antagonista receptora EP4 do leczenia raka jelita grubego stabilnego mikrosatelitarnego. Firma została zarejestrowana w 2016 roku i ma siedzibę w Bostonie w stanie Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 67 320 050
Aktywa: 148 988 000
Cena: 1.4
Wskaźnik Altman Z-Score: -0.1
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.6
Ilość akcji w obrocie: 52%
Średni wolumen: 89 101
Ilość akcji 48 258 100
Wskaźniki finansowe
Przychody TTM 659 000
Zobowiązania: 14 756 000
Przedział 52 tyg.: 0.971 - 1.94
Piotroski F-Score: 1
Słaby (niska jakość finansowa)
EPS: -0.9
P/E branży: 26.1
Beta: 0.485
Raport okresowy: 2025-08-06
WWW: https://ikenaoncology.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Mark Manfredi Ph.D. President, Chief Executive Officer & Director 810 694 1971
Dr. Jotin Marango M.D., Ph.D. Chief Operating Officer, Chief Financial Officer & Head of Corporate Development 577 120 1979
Mr. Jeffrey Ecsedy Ph.D. Chief Development Officer 0 1970
Mr. Bob Lally Senior Vice President of Finance & Operations 0 0
Dr. Caroline Germa M.D., Ph.D. Chief Medical Officer 0 1972
Ms. Rebecca Cohen Vice President of Investor Relations, Corporate Strategy & Communication 0 0
Mr. Navin Parwani M.S. Vice President & Head of Quality 0 0
Mr. David Damphousse M.S. Senior Vice President of Clinical Development Operations 0 0
Mr. Valdas Jurkauskas Ph.D. Senior Vice President of Technical Operations 0 0
Wiadomości dla Ikena Oncology, Inc.
Tytuł Treść Źródło Aktualizacja Link
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-12-30 15:01:14 Czytaj oryginał (ang.)
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function globenewswire.com 2024-12-23 10:37:00 Czytaj oryginał (ang.)
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function globenewswire.com 2024-12-23 10:30:00 Czytaj oryginał (ang.)
Ikena Oncology Reports Third Quarter 2024 Financial Results Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter globenewswire.com 2024-11-07 10:30:00 Czytaj oryginał (ang.)
Ikena Oncology Reports Second Quarter 2024 Financial Results Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter globenewswire.com 2024-08-08 20:15:00 Czytaj oryginał (ang.)
Best Momentum Stocks to Buy for July 12th IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024. zacks.com 2024-07-12 15:15:24 Czytaj oryginał (ang.)
New Strong Buy Stocks for July 12th USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024. zacks.com 2024-07-12 11:40:17 Czytaj oryginał (ang.)
UPDATE – Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. globenewswire.com 2024-05-28 20:42:00 Czytaj oryginał (ang.)
Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. globenewswire.com 2024-05-28 20:15:00 Czytaj oryginał (ang.)
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an update regarding its organization and pipeline. globenewswire.com 2024-05-13 20:45:00 Czytaj oryginał (ang.)
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. globenewswire.com 2024-04-10 12:00:00 Czytaj oryginał (ang.)
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline. globenewswire.com 2024-03-12 10:00:00 Czytaj oryginał (ang.)
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA. The Company will also be holding one-on-one investor meetings at the conference. globenewswire.com 2024-02-27 10:00:00 Czytaj oryginał (ang.)
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise globenewswire.com 2024-02-21 18:15:00 Czytaj oryginał (ang.)
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Ikena Oncology, Inc. (IKNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2024-02-14 12:37:05 Czytaj oryginał (ang.)
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com 2024-01-24 12:36:06 Czytaj oryginał (ang.)
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources from exploratory discovery to clinical development of IK-930 and IK-595 Ended 2023 in strong financial position with approximately $175 million in cash; runway extended into 2H 2026 BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, IK-930 and IK-595. The Company also announced an organizational streamlining that allows for the reallocation of resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs. globenewswire.com 2024-01-18 18:05:00 Czytaj oryginał (ang.)
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions globenewswire.com 2023-11-09 09:00:00 Czytaj oryginał (ang.)
Ikena Oncology to Present at Multiple November 2023 Investor Conferences BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November. globenewswire.com 2023-11-07 10:00:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of fiduciary duty. To obtain additional information, go to: https://zlk.com/compensation2/ikena-oncology-inc-lawsuit-submission-form   or contact Joseph E. prnewswire.com 2023-10-02 09:45:00 Czytaj oryginał (ang.)